Pibrentasvir
Active ingredient
Sold as MAVIRET
- Drug class
- -
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 2
Overview
Pibrentasvir is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 1 | February 10, 2026 |
| GB United Kingdom | MHRA | 1 | October 25, 2024 |
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [1].
Brands in Canada (1)
GBUnited Kingdom· MHRA
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Sources & citations
- [1]Health Canada (DPD) · 02467550 · revised February 10, 2026
- [2]MHRA (UK) · PLPI459850847 · revised October 25, 2024
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.